Victory Square Technologies enters into manufacturing agreement for rapid antibody testing
Victory Square Technologies signs new agreement to manufacture and supply testing globally to meet demand
VANCOUVER — Victory Square Technologies Inc. has entered into two Manufacturing, Sales and Distribution Agreements to supply White Label Covid-19 Rapid Antibody and Antigen Tests to be distributed through the company’s global distribution network, as well as sold online through the company’s ecommerce channels.
The agreements will also supply Victory Square with access to manufacture, sell and distribute other White Label diagnostic tests that will be available on the Company’s telehealth platform to be launched shortly.
The Covid-19 Rapid Antibody Tests have FDA Permission under EUA for sale & distribution in the United States and the CE Designation for sale & distribution throughout the European Union. The Covid-19 Rapid Antigen Tests come with the CE Designation for sale & distribution throughout the European Union.
These agreements will alleviate the supply and packaging challenges the company is currently facing due to the high demand for the company’s Safetest Rapid Tests in the country of origin – Brazil.
“These new supply channels will allow us to increase capacity, improve turn-around times, and lower costs by approximately 30%” said Shafin Diamond Tejani, CEO. Tejani goes on to say, “Victory Square has built up a global sales network over the past couple of months. These new manufacturing agreements will eliminate the supply bottleneck and enable the company and its agents to continue selling the Covid-19 Rapid Tests.”